Is local biotransformation the key to understanding the pharmacological activity of salicylates and gold drugs?

Inflammation Research

Volumn 45, Issue 12, 1996, Pages 579-582

  Whitehouse, M W ^a,b   Graham, G G ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Arthritis; Aurocyanide; Gentisate; Gold; Salicylate

Indexed keywords

GENTISIC ACID; GOLD COMPLEX; GOLD CYANIDE; GOLD DERIVATIVE; HYDROXYBENZOIC ACID; HYDROXYBENZOIC ACID DERIVATIVE; MYELOPEROXIDASE; QUINONE DERIVATIVE; SALICYLIC ACID DERIVATIVE;

ARTHRITIS; DRUG TRANSFORMATION; HUMAN; INFLAMMATION; NEUTROPHIL; SHORT SURVEY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; BIOTRANSFORMATION; CYANIDES; GOLD COMPOUNDS; HUMANS; HYDROXYLATION; MONOCYTES; NEUTROPHILS; OXIDATION-REDUCTION; PEROXIDASE; SALICYLATES;

EID: 0030479832     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02312038     Document Type: Short Survey

References (22)

1. Danpure C, Fyfe DA, Gumpel JM. Distribution of gold among plasma fractions in rheumatoid patients undergoing chrysotherapy compared with its distribution in plasma incubated with aurothiomalate in vitro. Ann Rheum Dis 1979;38:364-70.
2. Stelmaszynska T. Formation of HCN and its chlorination to ClCN by stimulated human neutrophils-2. Oxidation of thiocyanate as a source of HCN. Int J Biochem 1986;8: 1107-14.
3. Graham GG, Bales JR, Grootveld MC, Sadler PJ, 1H, 13C NMR, and electronic absorption spectroscopic studies of the interaction of cyanide with aurothiomalate. J Inorg Biochem 1985;25:163-73
4. Lewis G, Shaw GF. Competition of thiols and cyanide for gold (I). Inorg Chem 1986;25:58-62.
5. Graham GG, Dale MM. The activation of gold complexes by cyanide produced by polymorphonuclear leukocytes. II. Evidence for the formation and biological activity of aurocyanide. Biochem Pharmacol 1990;39:1697-702.
6. Rudkowski R, Graham GG, Champion GD, Ziegler JB. The activation of gold complexes produced by polymorphonuclear leukocytes. 1. The effects of aurocyanide on the oxidative burst of polymorphonuclear leukocytes. Biochem Pharmacol 1990; 39:1687-95.
7. Graham GG, Champion GD, Ziegler JB. The cellular metabolism and effects of gold complexes. Metal-based Drugs 1994;1:395-404.
8. DeChatelet LR, McPhail LC, Shirley PS. Effect of cyanide on NADPH oxidation by granules from human polymorphonuclear leukocytes. Blood 1977;49:445-54.
9. 2 ] in the formation of gold metabolites. Metal-based Drugs 1994;1:351-62.
10. Schuhmann D, Kubicka-Muranyi M, Mirtschewa J, Günther J, Kind P, Gleichmann E. Adverse immune reactions to gold. I. Chronic treatment with an Au(I) drug sensitizes mouse T cells not to Au(I), but to Au(III) and induces autoantibody formation. J Immunol 1990;145:2132-9.
11. Davis WB, Mohammed BS, Mays DC, She Z-W, Mohammed JR, Husney RM, et al. Hydroxylation of salicylate by activated neutrophils. Biochem Pharmacol 1989;38:4013-9.
12. Kettle AJ, Winterbourn CC. Superoxide-dependent hydroxylation by myeloperoxidase. J Biol Chem 1994;269:17146-51.
13. Betts WH, Whitehouse MW, Cleland LG, Vernon-Roberts B. In vitro antioxidant properties of potential biotransformation products of salicylate, sulphasalazine and amidopyrine. J Free Rad Biol Med 1985;1:273-80.
14. Haynes DR, Wright PFA, Gadd SJ, Whitehouse MW, Vernon-Roberts B. Is aspirin a prodrug for antioxidant and cytokine modulating antimetabolites? Agents Actions 1993;39:49-58.
15. Holmes TJ, John V, Vennerstrom J, Kulmacz RJ, Lands WEM. Stimulation of the cyclooxygenase activity of prostaglandin H synthase by salicylate-derived quinhydrones. Prostaglandins 1984;28:711-6.
16. Holmes TJ, Vennerstrom JL, John V. Inhibition of cyclooxygenase mediated by electrochemical oxidation of gentisic acid. J Biol Chem 1985;260:14092-5.
17. Kyle ME, Kocsis JJ. The effect of mixed function oxidase induction and inhibition on salicylate-induced nephrotoxcity in male rats. Toxicol Appl Pharmacol 1986;44:241-9.
18. 14C-homogentisic acid in connective tissues of rats with experimental alcaptonuria. Nature 1970;228:770-1.
19. Graziano JH, Grady RW, Cerami A. The identification of 2,3-dihydroxybenzoic acid as a potentially useful iron-chelating agent. J Pharmacol Exp Ther 1974;190:570-5.
20. Levy G, Tsuchiya T, Amsel LP. Limited capacity for salicyl phenolic glucuronide and its effect on the kinetics of salicylate elimination in man. Clin Pharmacol Ther 1972;13:258-68.
21. Kettle AJ, Winterbourn CC. Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs. Biochem Pharmacol 1991;41:1485-92.
22. van Gent A, Guille J, Graham GG, Day RO. Effect of salicylate and its metabolites on polymorphonuclear leukocytes. Clin Exp Pharmacol Physiol 1991;Suppl 18:63.